Published in Pharm Res on February 19, 2015
Fitting Transporter Activities to Cellular Drug Concentrations and Fluxes: Why the Bumblebee Can Fly. Trends Pharmacol Sci (2015) 0.86
Mechanistic studies of the transport of peimine in the Caco-2 cell model. Acta Pharm Sin B (2016) 0.75
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (2005) 4.13
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov (2008) 1.93
Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev (2007) 1.91
Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem (2008) 1.78
Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov (2010) 1.73
BDDCS applied to over 900 drugs. AAPS J (2011) 1.68
Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol Aspects Med (2013) 1.33
pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res (2003) 1.13
Monocarboxylic acid transport. Compr Physiol (2013) 1.13
The promiscuous binding of pharmaceutical drugs and their transporter-mediated uptake into cells: what we (need to) know and how we can do so. Drug Discov Today (2012) 1.10
The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release (2004) 1.09
Pharmaceutical drug transport: the issues and the implications that it is essentially carrier-mediated only. Drug Discov Today (2011) 1.05
Jejunal permeability: a comparison between the ussing chamber technique and the single-pass perfusion in humans. Pharm Res (1997) 1.02
The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol (1968) 1.01
The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci (2012) 1.00
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol (2014) 1.00
Implications of the dominant role of transporters in drug uptake by cells. Curr Top Med Chem (2009) 0.99
Regulation of the gene encoding the intestinal bile acid transporter ASBT by the caudal-type homeobox proteins CDX1 and CDX2. Am J Physiol Gastrointest Liver Physiol (2011) 0.94
Stereoselective hemodynamic effects of (R)-and (S)-propranolol in man. Naunyn Schmiedebergs Arch Pharmacol (1989) 0.90
Evidence-based approach to assess passive diffusion and carrier-mediated drug transport. Drug Discov Today (2012) 0.87
The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol (2000) 0.85
Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine. J Pharmacol Exp Ther (2002) 0.84
Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers. Pharm Res (2000) 0.82
Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier. Pharm Res (2012) 0.82
Propranolol transport across the inner blood-retinal barrier: potential involvement of a novel organic cation transporter. J Pharm Sci (2013) 0.82
Stereoselective transport and uptake of propranolol across human intestinal Caco-2 cell monolayers. Chirality (2010) 0.80
Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. Pharm Res (2008) 0.79
Stereoselective accumulation of propranolol enantiomers in K562 and K562/ADR cells. Chirality (2013) 0.78
Sotalol permeability in cultured-cell, rat intestine, and PAMPA system. Pharm Res (2012) 0.77
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (2005) 4.13
Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev (2007) 1.91
Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther (2005) 1.67
Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther (2002) 1.64
Effects of renal failure on drug transport and metabolism. Pharmacol Ther (2005) 1.53
The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res (2009) 1.46
Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J (2009) 1.43
Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet (2002) 1.41
Music therapy for people with schizophrenia and schizophrenia-like disorders. Cochrane Database Syst Rev (2011) 1.20
Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv (2004) 1.19
Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther (2010) 1.15
The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res (2008) 1.12
The BCS, BDDCS, and regulatory guidances. Pharm Res (2011) 1.11
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr (2009) 1.10
Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation (2005) 1.10
Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy (2011) 1.09
Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos (2006) 1.08
Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4. J Infect Dev Ctries (2008) 1.06
Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther (2002) 1.04
Effects of drug transporters on volume of distribution. AAPS J (2009) 1.01
Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos (2004) 1.01
Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm (2013) 1.00
In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos (2006) 1.00
Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci (2002) 1.00
CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther (2003) 0.99
Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos (2004) 0.99
Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos (2003) 0.97
Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet (2003) 0.97
P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res (2004) 0.96
Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther (2006) 0.95
Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol (2004) 0.93
Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res (2002) 0.93
In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther (2003) 0.93
Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev (2011) 0.92
Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. Pharm Res (2013) 0.92
High-performance liquid chromatography spectrometric analysis of trans-resveratrol in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.92
Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos (2006) 0.91
Intestinal drug transporters: an overview. Adv Drug Deliv Rev (2012) 0.91
Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther (2003) 0.90
BDDCS class prediction for new molecular entities. Mol Pharm (2012) 0.89
Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J Clin Pharmacol (2005) 0.88
Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients. Transplantation (2014) 0.87
Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci (2011) 0.87
Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther (2002) 0.87
Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. Chem Res Toxicol (2002) 0.86
PET imaging of Oatp-mediated hepatobiliary transport of [(11)C] rosuvastatin in the rat. Mol Pharm (2014) 0.86
Comparative study on preparative methods of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation efficiency. Int J Pharm (2012) 0.86
Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom (2007) 0.86
Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology (2002) 0.85
Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit (2004) 0.85
Protective effect of glycyrrhizin, glycyrrhetic acid and matrine on acute cholestasis induced by alpha-naphthyl isothiocyanate in rats. Planta Med (2007) 0.84
Lead PK commentary: predicting human pharmacokinetics. J Pharm Sci (2011) 0.84
Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci (2009) 0.84
Is Ciprofloxacin a Substrate of P-glycoprotein? Arch Drug Inf (2011) 0.83
Predicting when biliary excretion of parent drug is a major route of elimination in humans. AAPS J (2014) 0.83
Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med (2002) 0.83
Comparison of the effects of cyclosporin a on the metabolism of perfused rat brain slices during normoxia and hypoxia. J Cereb Blood Flow Metab (2002) 0.82
Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology (Carlton) (2005) 0.82
Studies on the reactivity of clofibryl-S-acyl-CoA thioester with glutathione in vitro. Drug Metab Dispos (2002) 0.81
Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol Pharm (2014) 0.81
Pharmacokinetics and disposition study of calf thymus DNA in rats by applying 3H-labeling method. J Pharm Biomed Anal (2012) 0.81
Pharmacokinetics, tissue distribution, and plasma protein binding study of platinum originating from dicycloplatin, a novel antitumor supramolecule, in rats and dogs by ICP-MS. Biol Trace Elem Res (2012) 0.81
Comparison of bidirectional cephalexin transport across MDCK and caco-2 cell monolayers: interactions with peptide transporters. Pharm Res (2002) 0.81
Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol (2011) 0.81
Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. Mol Pharm (2005) 0.79
Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients. Drug Metab Dispos (2011) 0.79
Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab Dispos (2009) 0.79
Identification of human UDP-glucuronosyltransferase isoforms responsible for the glucuronidation of glycyrrhetinic acid. Drug Metab Pharmacokinet (2009) 0.79
Quantitative liquid chromatography-mass spectrometry determination of isatin in urine using automated on-line extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.79
The nonenzymatic reactivity of the acyl-linked metabolites of mefenamic acid toward amino and thiol functional group bionucleophiles. Drug Metab Dispos (2013) 0.79
Efficacy, pharmacokinetics, and biodistribution of thermosensitive chitosan/β-glycerophosphate hydrogel loaded with docetaxel. AAPS PharmSciTech (2014) 0.79
In vitro and in vivo studies on acyl-coenzyme A-dependent bioactivation of zomepirac in rats. Chem Res Toxicol (2005) 0.78
Enantioselective covalent binding of 2-phenylpropionic Acid to protein in vitro in rat hepatocytes. Chem Res Toxicol (2002) 0.78
Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes. Drug Metab Dispos (2010) 0.78
Age and sex differences in the effects of the immunosuppressants cyclosporine, sirolimus and everolimus on rat brain metabolism. Neurotoxicology (2010) 0.78
Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection. J Pharm Pharmacol (2014) 0.78
[Influence of glycyrrhizin on paeoniflorin pharmacokinetic fate in unrestrained conscious rats by intravenous administration]. Zhongguo Zhong Yao Za Zhi (2009) 0.78
Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort. Eur J Clin Pharmacol (2009) 0.78
Gastric reacidification with betaine HCl in healthy volunteers with rabeprazole-induced hypochlorhydria. Mol Pharm (2013) 0.78
Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation. J Pharmacokinet Pharmacodyn (2011) 0.78
Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal transplant patients: a preliminary evaluation. J Clin Pharmacol (2002) 0.78
Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Eur J Drug Metab Pharmacokinet (2011) 0.77
Investigation on pharmacokinetics, tissue distribution and excretion of a novel platinum anticancer agent in rats by inductively coupled plasma mass spectrometry (ICP-MS). Xenobiotica (2014) 0.77
Pharmacokinetics of vicagrel, a promising analog of clopidogrel, in rats and beagle dogs. J Pharm Sci (2012) 0.77
In vitro cytotoxicity, pharmacokinetics and tissue distribution in rats of MXN-004, a novel conjugate of polyethylene glycol and SN38. Xenobiotica (2013) 0.77
Altered expression of Armet and Mrlp51 in the oocyte, preimplantation embryo, and brain of mice following oocyte in vitro maturation but postnatal brain development and cognitive function are normal. Reproduction (2011) 0.77
Pharmacokinetics in Sprague-Dawley rats and Beagle dogs and in vitro metabolism of ZJM-289, a novel nitric dioxide donor. Xenobiotica (2013) 0.77
Novel percutaneous adventitial drug delivery system for regional vascular treatment. Catheter Cardiovasc Interv (2004) 0.77
Determination of nimodipine in human plasma by HPLC-ESI-MS and its application to a bioequivalence study. J Chromatogr Sci (2010) 0.77
Sotalol permeability in cultured-cell, rat intestine, and PAMPA system. Pharm Res (2012) 0.77
Contributions of intestine and plasma to the presystemic bioconversion of vicagrel, an acetate of clopidogrel. Pharm Res (2013) 0.77